174 related articles for article (PubMed ID: 34652758)
1. Real-world results of direct-acting antivirals use for the treatment of chronic hepatitis C in old patients.
El Kassas M; El Sheemy R; Alboraie M; El Badry M; Wifi MN; Youssef N; Ezzat S; Tahoon M; Abdelsalam L; Abdelhakam SM; Ali-Eldin Z
Eur Geriatr Med; 2019 Apr; 10(2):295-302. PubMed ID: 34652758
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, Safety, and Predictors of Direct-acting antivirals in Hepatitis C Virus Patients with Heterogeneous Liver Diseases.
De Pace V; Morelli MC; Ravaioli M; Maggi F; Galli S; Vero V; Re MC; Cescon M; Pistello M
New Microbiol; 2019 Oct; 42(4):189-196. PubMed ID: 31609453
[TBL] [Abstract][Full Text] [Related]
3. Real world experience with the all-oral interferon free regimen for the treatment of chronic hepatitis c virus infection in the Lebanese population.
Saba J; Abou Rached A; Yaghi C; Sharara A; Ammar W
J Infect Dev Ctries; 2018 Feb; 12(2.1):30S. PubMed ID: 31805005
[TBL] [Abstract][Full Text] [Related]
4. Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy.
Milazzo L; Lai A; Calvi E; Ronzi P; Micheli V; Binda F; Ridolfo AL; Gervasoni C; Galli M; Antinori S; Sollima S
HIV Med; 2017 Apr; 18(4):284-291. PubMed ID: 27477612
[TBL] [Abstract][Full Text] [Related]
5. The outcome of combined treatment with ombitasvir-paritaprevir-ritonavir, sofosbuvir with or without ribavirin as salvage therapy for Egyptian HCV experienced patients: A single center study.
Ismail WA; Wadea FM
Drug Discov Ther; 2018; 12(6):368-373. PubMed ID: 30674772
[TBL] [Abstract][Full Text] [Related]
6. High rates of hepatitis C virus (HCV) cure using direct-acting antivirals in HIV/HCV-coinfected patients: a real-world perspective.
Hawkins C; Grant J; Ammerman LR; Palella F; Mclaughlin M; Green R; Mcgregor D; Stosor V
J Antimicrob Chemother; 2016 Sep; 71(9):2642-5. PubMed ID: 27330060
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
Calleja JL; Crespo J; Rincón D; Ruiz-Antorán B; Fernandez I; Perelló C; Gea F; Lens S; García-Samaniego J; Sacristán B; García-Eliz M; Llerena S; Pascasio JM; Turnes J; Torras X; Morillas RM; Llaneras J; Serra MA; Diago M; Rodriguez CF; Ampuero J; Jorquera F; Simon MA; Arenas J; Navascues CA; Bañares R; Muñoz R; Albillos A; Mariño Z;
J Hepatol; 2017 Jun; 66(6):1138-1148. PubMed ID: 28189751
[TBL] [Abstract][Full Text] [Related]
8. Real-world safety and effectiveness of retreatment of Egyptian chronic hepatitis C patients not responding to NS5A inhibitor-based therapies.
Yousif MM; Ahmed H; Elsadek HM; Shendi AM; Gouda TM; Elsayed IA; Gendia MA; Magdy MM; Lbrahim NF; Sadek AMEM; Zaki AM; Shafeik H; Zahran MH
J Viral Hepat; 2020 Nov; 27(11):1190-1201. PubMed ID: 32564500
[TBL] [Abstract][Full Text] [Related]
9. Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: Results from the multicenter German hepatitis C cohort (GECCO-03).
Wehmeyer MH; Ingiliz P; Christensen S; Hueppe D; Lutz T; Simon KG; Schewe K; Boesecke C; Baumgarten A; Busch H; Rockstroh J; Schmutz G; Kimhofer T; Berger F; Mauss S; Schulze Zur Wiesch J
J Med Virol; 2018 Feb; 90(2):304-312. PubMed ID: 28710853
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and safety of generic and brand direct acting antivirals for treatment of chronic hepatitis C.
Abdulla M; Al Ghareeb AM; Husain HAHY; Mohammed N; Al Qamish J
World J Clin Cases; 2022 Dec; 10(34):12566-12577. PubMed ID: 36579085
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C treatment with all-oral direct-acting antivirals: Effectiveness and tolerance in a multicenter, prospective, observational study from French general hospitals (APROVVIE, ANGH).
Pariente A; Arpurt JP; Rémy AJ; Rosa-Hézode I; Causse X; Heluwaert F; Macaigne G; Henrion J; Renou C; Schnee M; Salloum H; Hommel S; Pilette C; Arotcarena R; Barjonet G; Lison H; Bourhis F; Jouannaud V; Pauwels A; Le eaBricquir Y; Geagea E; Condat B; Ripault MP; Zanditenas D; de Montigny-Lenhardt S; Labadie H; Tissot B; Maringe E; Cadranel JF; Hagège H; Lesgourgues B;
Presse Med; 2019 Mar; 48(3 Pt 1):e101-e110. PubMed ID: 30853287
[TBL] [Abstract][Full Text] [Related]
12. Baseline resistance associated substitutions in HCV genotype 1 infected cohort treated with Simeprevir, Daclatasvir and Sofosbuvir in Brazil.
Aguiar BF; Campos GRF; Rodrigues JPV; Marques NN; Molina BF; Bittar C; Souza FF; Martinelli ALC; Rahal P; Pereira LRL
Clin Res Hepatol Gastroenterol; 2020 Jun; 44(3):329-339. PubMed ID: 31523019
[TBL] [Abstract][Full Text] [Related]
13. Retreatment of chronic hepatitis C virus genotype-4 patients after non-structural protein 5A inhibitors' failure: efficacy and safety of different regimens.
El-Khayat H; Kamal EM; Mahmoud H; Gomaa A; Ebeid B; Sameh Y; Hasseb A; El Raziky M; El Serafy M; Doss W; Esmat G; Fouad Y; Attia D
Eur J Gastroenterol Hepatol; 2020 Mar; 32(3):440-446. PubMed ID: 31688311
[TBL] [Abstract][Full Text] [Related]
14. Real-world effectiveness and safety of sofosbuvir plus daclatasvir with or without ribavirin for genotype 2 chronic hepatitis C in Taiwan.
Cheng PN; Chiu YC; Chien SC; Chiu HC
J Formos Med Assoc; 2019 May; 118(5):907-913. PubMed ID: 30316677
[TBL] [Abstract][Full Text] [Related]
15. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: Real-world data.
Hong CM; Liu CH; Su TH; Yang HC; Chen PJ; Chen YW; Kao JH; Liu CJ
J Microbiol Immunol Infect; 2020 Aug; 53(4):569-577. PubMed ID: 30316726
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Sofosbuvir-Based Direct Acting Antivirals for Hepatitis C in Septuagenarians and Octogenarians.
Snyder HS; Ali B; Gonzalez HC; Nair S; Satapathy SK
J Clin Exp Hepatol; 2017 Jun; 7(2):93-96. PubMed ID: 28663671
[TBL] [Abstract][Full Text] [Related]
17. Integrated Care for the Use of Direct-acting Antivirals in Patients With Chronic Hepatitis C and Substance Use Disorder.
Trabut JB; Barrault C; Charlot H; Carmona D; Bourdel A; Benslimane M; François M; Kini-Matondo W; Causse R; Roudot-Thoraval F; Hézode C
J Addict Med; 2018; 12(5):346-352. PubMed ID: 29702515
[TBL] [Abstract][Full Text] [Related]
18. Ledipasvir/Sofosbuvir versus Daclatasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype 4 Patients.
Abdelaty LN; Elnaggar AA; Said AA; Hussein RRS
Curr Drug Saf; 2020; 15(1):53-60. PubMed ID: 31573893
[TBL] [Abstract][Full Text] [Related]
19. Adding ribavirin to newer DAA regimens does not affect SVR rates in HCV genotype 1 infected persons: results from ERCHIVES.
Butt AA; Yan P; Marks K; Shaikh OS; Sherman KE;
Aliment Pharmacol Ther; 2016 Oct; 44(7):728-37. PubMed ID: 27459341
[TBL] [Abstract][Full Text] [Related]
20. Retreatment Efficacy of Sofosbuvir/Ombitasvir/Paritaprevir/Ritonavir + Ribavirin for Hepatitis C Virus Genotype 4 Patients.
Abdel-Moneim A; Aboud A; Abdel-Gabbar M; Zanaty M; Ramadan M
Dig Dis Sci; 2018 May; 63(5):1341-1347. PubMed ID: 29546644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]